Deferoxamine

• Desferrioxamine
• N'- [5 - ( acetyl -hydroxy- amino) pentyl] -N-[ 5 - [3 - (5- aminopentyl -hydroxy- carbamoyl) propanoylamino ] pentyl ]-N -hydroxy- butanediamide

• 70-51-9
• 138-14-7 ( deferoxamine mesylate)

V03AC01

Antidote

Chelating agents

140 ° C

Template: Infobox chemical / molecular formula search available

Deferoxamine is a drug that is used because of its high affinity for trivalent iron ion and its chelating capacity as an antidote for poisoning with iron. It is marketed by Novartis in Germany, Austria, Switzerland and the rest of the EU under the name Desferal.

Pharmacological properties

Deferoxamine has a higher molecular weight compound having three hydroxamic groups and has a high affinity for iron ( III) ions. It binds with the hemoglobin degradation liberated iron and causes its renal excretion. Iron deficiency symptoms do not occur with short-term use.

Clinical information

Areas of application (indications )

Deferoxamine is used as peroral and parenteral drug appliqued with iron overload, including in hemochromatosis, sideroblastic anemia, secondary hemosiderosis after blood transfusions and acute iron poisoning.

The deferoxamine - test is used to determine pathological iron deposits. Simultaneously, a pathological deferoxamine test ( Desferal test) an indication of the presence of an aluminum- induced osteopathy ( low turnover osteopathy ) be.

Other Information

Deferoxamine is found in nature as a reddish dye in Streptomyces pilosus actinobacterium.